Sector News

Flannery wins top GE job after nursing growth at healthcare unit

June 13, 2017
Life sciences

When John Flannery was chosen to head GE Healthcare in 2014, his background as chief dealmaker for the industrial conglomerate led to speculation GE might consider spinning off its somewhat sickly health business.

In fact, he has nursed it back to improving sales and profits by focusing primarily on organic growth opportunities, and the business remains core to GE.

Flannery will take over General Electric Co from Jeff Immelt, who is stepping aside after 16 years as head of the conglomerate he helped steer through the financial crisis but which is now worth a third less than when he took over.

On Flannery’s watch, the healthcare unit – best-known for imaging and diagnostics – has also expanded into life sciences, offering a range of services to pharmaceutical and biotech companies.

GE faces tough competition for its medical imaging machines, which include MRI scanners and ultrasound devices, from rivals including Philips and Siemens, as well as younger Asian upstarts.

But a focus on expansion into new markets has helped lift sales at GE Healthcare to $18.3 billion last year, with organic revenue increasing by 5 percent and margins by 100 basis points.

Flannery has worked hard to move GE into newer areas of healthcare like life sciences, where GE has emerged as a significant player in helping with the production of biological drugs and cell therapies.

Such drugs, given by injection or infusion, are a pivotal driver of innovation in the drugs industry, being used to treat complex diseases from rheumatoid arthritis to cancer.

Flannery told Reuters last year he aimed to “double down on life sciences”, given this business’s large and high-margin opportunities.

One of the more innovative ideas launched by GE recently is the design of prefabricated drug factories for making complex biotech medicines, an idea it is pioneering in both China and Ireland.

GE reckons its “off-the-shelf” modular factories are 25 to 50 percent cheaper than the traditional plants and can be constructed in just 18 months rather than the typical three years.

Some analysts continue to question whether healthcare truly fits with mainstay GE industries like power generation and jet engines, but Flannery’s elevation suggests the group is not contemplating ditching healthcare any time soon.

In a sign of continuity, GE said Kieran Murphy, who currently heads life sciences, would lead the wider GE Healthcare division – and the company stated bluntly: “Healthcare is a key GE business now and in the future.”

By Ben Hirschler

Source: Reuters

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach